NORMA FLORES: Open Payments
NPI 1811371537 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,305 in 97 payments from 16 companies in 2025. Trend: 2023 $1,871 · 2024 $2,873 · 2025 $3,305
Food & beverage: $3,305
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $800 |
| E.R. Squibb & Sons, L.L.C. | 21 | $487 |
| AstraZeneca Pharmaceuticals LP | 9 | $339 |
| SCPHARMACEUTICALS INC. | 6 | $304 |
| PFIZER INC. | 11 | $214 |
| Alnylam Pharmaceuticals Inc. | 7 | $186 |
| Medtronic, Inc. | 1 | $182 |
| Novo Nordisk Inc | 7 | $149 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $135 |
| Boston Scientific Corporation | 2 | $118 |
Products named: JARDIANCE, FUROSCIX, ELIQUIS, AMVUTTRA, Kerendia, VYNDAQEL, LOKELMA, Wegovy.
Industry payments across MD — which companies pay providers there.
